Delta 9 THC [BSA]

The primary active component of the Cannabis plant (Cannabis sativa and Cannabis indica) known as 9 tetrahydrocannabinol (THC) is one of the extensively researched phytocannabinoids, with well documented effects on the human body and mind based on its chemical composition C21H30 O2. Its unique structure includes a form along, with an alkyl chain and a hydroxyl functional group that contribute to its high lipophilicity; enabling it to efficiently traverse cell membranes and the blood brain barrier to interact with internal components. THC stands out not for its mind-altering effects but, for its wide range of medicinal properties and pharmacological functions in cannabis plants. The production of THC in cannabis involves a chain of enzyme driven reactions starting from the compound acid (CBGA). This precursor is transformed into acid (THCA) with the help of THCA synthase enzyme, before converting into the active THC through decarboxylation process. There is varying levels of THC, from strain to cultivation to processing. THC's psychoactivity is partially mediated by interactions with the endocannabinoid system (ECS), which consists of two receptors (CB1 and CB2) and endogenous ligands. THC is a selective agonist for the CB1 receptor; however, it is mostly found in the central nervous system. CB1 blocks brain-excitement neurotransmitters such as glutamate whose pain-, sedative and euphoric effects regulate appetite and memory. CB2 receptors control anti-inflammatory reactions and are mostly present on immune cells. THC's psychoactive effects stem from its selective activation of CB1, which has two sides: at low doses, THC reduces pain and anxiety, while at high doses, it produces anxiety and brain deformation.

Figure 1. Chemical Structures of Cannabinoids Δ9-Tetrahydrocannabinol (THC), Cannabidiol (CBD), and Cannabidivarin (CBDV). (Source: Alves P, et al., 2020)

The pharmacokinetics of THC dictate its duration and effectiveness. The most common route of administration is via inhalation with a 10%-35% bioavailability.' Very fast-acting, the plasma level jumps within minutes, and immediate psychoactive and physiological effects. The oral form of the substance undergoes processing, by the liver initially (around 6% 19%) but it stays active in the body for longer periods and is considered suitable for treating chronic conditions. Subsequently in the livers metabolic process involving enzymes like CYP2Cl and CYP34a converts THC into 11 THC (11 OHIHC) a compound that affects functions and is further converted into 11 nor g carboxyl THC (11 COOIHC) which serves as a marker, for drug testing despite lacking psychoactive effects. Painkillers, anti-emetic and appetite suppressants are the most widely prescribed THC uses. Two THC drugs were approved for chemotherapy nausea and vomiting, and AIDS anorexia. These drugs work in patients who do not respond to traditional antiemetics, and boost their diet and quality of life. THC is also used to alleviate chronic pain, especially neuropathic pain in conditions like multiple sclerosis. THC, researchers have revealed, regulates signaling to the peripheral nervous system via CB1 receptors to stop release of inflammatory mediators, thus reducing pain. Yet THC's psychoactive properties have been tightly controlled in most states, and some users suffer from cognitive side effects. THC has shown promise in the arena of neuroprotection. THC has been tested experimentally in the presence of excitotoxicity and oxidative stress, preventing cell death. In animal Parkinson's disease, for instance, THC prevented dopaminergic cell death via activation of the CB1 and CB2 receptors. In addition, THC has been implicated in anti-inflammatory activity in Alzheimer's disease by inhibiting inflammatory cytokines including TNF- and IL-1 that promote neuroinflammatory relief. But the ramifications of THC's psychoactivity deserve deeper consideration.

For all its medical virtues, THC is vulnerable to abuse and addiction. Chronic THC exposure depresses and inhibits the function of the CB1 receptor, weakening its therapeutic capacity, and possibly triggering mood swings and brain dysfunction. Further, overconsumption of adolescent THC has been linked to an increased risk of schizophrenia, perhaps because of its neurodevelopmental consequences. In an effort to minimize adverse reactions and maximize potency, researchers have developed new delivery vehicles, including liposomes, nanoemulsions and patches. These technologies enhance THC bioavailability, lowering first-pass metabolism and psychoactive effects, and represent promising drug development opportunities. Future THC research and use is expected to continue to expand. In one respect, combining molecular biology and pharmacology might allow it to be better understood as to how it functions, informing multi-target drug development. Conversely, experimenting with THC and other cannabinoids like CBD could generate more efficient and safer drug mixtures with fewer psychoactive side effects. THC's oncological application has also attracted attention. According to in vitro studies, THC suppresses the growth of tumor cells by turning them off and slowing angiogenesis, although this is still clinically questionable. Overall, THC is the most promising psychoactive compound currently being studied, and could potentially be used for a range of chronic ailments. However, its risks of misuse and societal controversy present challenges for its development and regulation. Through coordinated efforts in scientific research and policy-making, THC's future applications could expand, offering innovative solutions for neurological disorders, cancer, and inflammation-related conditions.

Delta-9-Tetrahydrocannabinol
Δ9-THC Conjugate
Δ9-THC BSA Conjugated Protein